Business
Master Service Agreement signed for Ox-1 programme
Master Service Agreement signed for Ox-1 programme.
About this update from Theracryf Plc
[{"type":"text","content":"\n\n \n\nTheraCryf plc\n(\"TheraCryf\", the \"Company\" or the \"Group\")\nMaster Service Agreement signed for Orexin-1 programme* development\n \nPharmaron appointed as contract research organisation\n \nAlderley Park, UK - 12 May 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on neuropsychiatry and oncology, has signed a Master Service Agreement (\"MSA\", or the \"Agreement\") with leading contract research organisation (\"CRO\") Pharmaron UK Ltd (\"Pharmaron\") to progress development of the Company's Orexin-1 (\"Ox-1\") addiction programme.\n \nUnder the Agreement, Pharmaron will provide services to enable completion of the remaining preclinical data packages necessary to support an application for clinical trial authorisation (IND/CTA). The activities will include manufacturing scale up, formulation and clinical drug supply together with regulatory-standard toxicology work - the last stages of preclinical drug development before administration in humans. As noted at the time of the Company's recent fundraise, a substantial part of the proceeds will be allocated to this new, key programme for the Company. Work under the MSA is expected to commence imminently, further information on each work package will be announced at initiation and completion, with full completion of all studies necessary for IND/CTA application anticipated in H2 2026.\n \nDr Huw Jones, TheraCryf CEO said:\n\"Following our £4.25m gross fundraise in the first quarter of this year, we are now moving at pace with our acquired and potentially most valuable programme, Ox-1. Blocking the Ox-1 receptor has the potential to alleviate a number of addictive and impulsive conditions. We look forward to proceeding towards clinical trials in man as quickly and efficiently as possible with Pharmaron as our development partner.\"\n \nDr Helen Kuhlman, TheraCryf CBO added:\n\"We evaluated a number of proposals from potential providers and throughout this rigorous process were impressed by the knowledge and expertise shown by the Pharmaron team. The positive external references we received regarding the quality and delivery of their work added to our confidence in selecting them as our provider to take the Orexin programme forward.\"\n \nDr Filipa Antunes, Pharmaron Business Executive Director...